As detailed in the attached press release from AB Industrivärden, Sverker Martin -Löf has announced his intention to leave his directorships at the companies’ coming Annual General Meetings. On condition that the Nomination Committee proposes the change to SCA’s Board at the forthcoming Annual General Meeting, as stated in the attached press release, and the 2015 Annual General Meeting resolves in accordance with the proposal, the current CEO of Handelsbanken, Pär Boman, will be appointed the Chairman of the Board. NB This information is such that SCA must disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication on January 22, 2015, at 08:20 CET. For further information, please contact: Karl Stoltz, Media Relations Manager, 46 8 788 51 55 SCA is a leading global hygiene and forest products company. The Group develops and produces sustainable personal care, tissue and forest products. Sales are conducted in about 100 countries under many strong brands, including the leading global brands TENA and Tork, and regional brands, such as Libero, Libresse, Lotus, Nosotras, Saba, Tempo and Vinda. As Europe’s largest private forest owner, SCA places considerable emphasis on sustainable forest management. The Group has about 44,000 employees. Sales in 2013 amounted to approximately SEK 93bn (EUR 10.7bn). SCA was founded in 1929, has its headquarters in Stockholm, Sweden, and is listed on NASDAQ OMX Stockholm. For more information, visit www.sca.com.
Proposal for new Chairman of SCA As detailed in the
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Next Ventures Invests in BranchLab to Enhance Healthcare AI
Next Ventures Makes Strategic Investment in BranchLab Next Ventures, a prominent venture capital firm dedicated to fostering advancements in whole-person health, has made an exciting strategic investment in BranchLab, a leader in AI-driven solutions for healthcare marketing. This collaboration aims to shift healthcare towards a proactive and interconnected model that...
Continue Reading
Cytokinetics Highlights Promising Aficamten Data for HCM
Cytokinetics, Incorporated (Nasdaq: CYTK) made waves back in 2024 when they released data from their pivotal Phase 3 clinical trial SEQUOIA-HCM, focusing on the investigational drug aficamten. This treatment targets symptomatic obstructive hypertrophic cardiomyopathy (HCM), a condition that can wreck lives with its debilitating symptoms. The big reveal came at the Heart...
Continue Reading
Totalkredit A/S: Comprehensive Insights into Cash Flows
Overview of Cash Flows at Totalkredit A/S At Totalkredit A/S, we emphasize transparency and clarity in our financial disclosures. Recently, we have conducted a comprehensive analysis of cash flows, focusing on various loan types including open and closed annuities, index-linked loans, and serial loans. This analysis reflects our commitment to maintaining robust financial...
Continue Reading
Bitcoin Approaches $70,000 Amid Regulatory Optimism
Bitcoin's steady climb towards the $70,000 mark back in 2024 was no accident—traders were watching the charts closely as a wave of inflows into exchange-traded funds (ETFs) linked to this digital heavyweight kicked off a bullish sentiment. With Bitcoin hovering around $68,720 during that time, it was clear that the market was feeling jittery, especially given how...
Continue Reading
Corporate Visions Welcomes Dom Maida to Enhance AI Strategy
Corporate Visions Welcomes Industry Leader to Board Corporate Visions, a recognized leader in evidence-based revenue growth solutions, has announced the appointment of tech veteran Dom Maida to its Board of Directors. Maida is known for his extensive experience in data, technology, and product development, especially from his tenure at Bloomberg where he served as Chief...
Continue Reading